Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.65 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.65 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.65 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300404 | 0.86 | ALDH1A1 (0.84) | L3MBTL1KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL19277768 | 0.86 | L3MBTL1 (0.74) | L3MBTL1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12490995 | 0.85 | L3MBTL1 (0.74) | L3MBTL1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4070839 | 0.85 | ALDH1A1 (0.84) | L3MBTL1KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL12793391 | 0.85 | GAA (0.79) | L3MBTL1KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL8644045 | 0.85 | ALDH1A1 (0.81) | L3MBTL1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4759272 | 0.84 | KMT2A (0.78) | L3MBTL1KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL12386394 | 0.83 | L3MBTL1 (0.71) | L3MBTL1KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL12010889 | 0.83 | ALDH1A1 (0.78) | L3MBTL1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12386393 | 0.82 | KMT2A (0.72) | L3MBTL1KMT2AMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0104353-B1 | HEAT SENSITIVE RECORD MATERIAL | HODOGAYA CHEMICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
| US-4482905-A | FLUORAN, BENZENESULFONAMIDE, ACID, BINDER | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-11-13 | — | — | US | claimed |
| EP-0104353-A2 | Heat sensitive record material | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-04-04 | — | — | EP | claimed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2002078970-A1 | HEAT SENSITIVE RECORDING MATERIAL | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | L3MBTL1 2235/4885KMT2A 1872/4885MEN1 3593/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | L3MBTL1 3590/4885KMT2A 3314/4885MEN1 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.